Hyota Takamatsu

15PUBLICATIONS
52CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)AutoimmunityApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jun 26, 2026
Achievement of intermediate treatment targets for Still's disease under tocilizumab treatment: a post-hoc analysis of the phase III trial.

|Jan 29, 2026
Long-term safety and efficacy of tocilizumab in adult-onset Still's disease: open-label, long-term extension of the phase III trial.

Koji Suzuki, Hideto Kameda, Kei Ikeda

|Nov 14, 2025
Identification of Histone Deacetylase Inhibitor Targeting Type I Interferon and B Cell Abnormalities in Systemic Lupus Erythematosus.

Takehiro Hirayama, Hachiro Konaka, Yasuhiro Kato

|Oct 25, 2025
Strong inhibition of IL-6 signal is clinically and serologically effective in refractory adult-onset Still's disease.

Koji Suzuki, Hideto Kameda, Kei Ikeda

|Jun 27, 2025
Mitochondrial DNA: leakage, recognition and associated human diseases.

Hyota Takamatsu

|Jun 14, 2025
Serum cytokine levels towards precision medicine in Still's disease: a subanalysis of a randomized controlled trial of tocilizumab.

Koji Suzuki, Hideto Kameda, Kei Ikeda

Pageof 3

Frequent Collaborators

6 joint publications

Atsushi Kumanogoh

5 joint publications

Masayuki Nishide

4 joint publications

Koji Suzuki

4 joint publications

Kosaku Murakami